The Technical Analyst
Eaton Vance Ohio [EVO]
Exchange: NYSE Sector: Healthcare Industry: Drug Manufacturers—Specialty & Generic
Eaton Vance Ohio Price, Forecast, Insider, Ratings, Fundamentals & Signals
0.97% $5.19
America/New_York / 8 mai 2024 @ 16:00
| FUNDAMENTALS | |
|---|---|
| MarketCap: | 1 840.29 mill |
| EPS: | -0.250 |
| P/E: | -20.76 |
| Earnings Date: | May 22, 2024 |
| SharesOutstanding: | 354.58 mill |
| Avg Daily Volume: | 0.113 mill |
| RATING 2024-05-08 |
|---|
| B |
| Neutral |
| RATINGS | ||
|---|---|---|
| Rating CashFlow: | Strong Buy | |
| Return On Equity: | Sell | |
| Return On Asset: | Sell | |
| DE: | Buy | |
| P/E: | Strong Sell | |
| Price To Book: | Neutral |
| QUARTER GROWTHS | ||||||
|---|---|---|---|---|---|---|
| 3/22 | 4/22 | 1/23 | 2/23 | 3/23 | 4/23 | |
| Revenue | ||||||
| Gr.Profit | ||||||
| Ebit | ||||||
| Asset | n/a | |||||
| Debt | n/a |
| PE RATIO: COMPANY / SECTOR |
|---|
| 0.00x |
| Company: PE -20.76 | sector: PE 15.43 |
| PE RATIO: COMPANY / INDUSTRY |
|---|
| -0.20x |
| Company: PE -20.76 | industry: PE 102.44 |
| DISCOUNTED CASH FLOW VALUE |
|---|
| N/A |
| N/A |
| Expected Trading Range (DAY) |
|---|
|
$ 4.93 - 5.45 ( +/- 5.01%) |
| ATR Model: 14 days |
Insider Trading
| Date | Person | Action | Amount | type |
|---|---|---|---|---|
| 2018-10-22 | Anderson Mark Monroe | Buy | 100 000 | Stock Option (right to buy) |
| 2018-10-22 | Anderson Mark Monroe | Buy | 0 | |
| 2018-08-13 | Smith Scott Clifford | Buy | 100 000 | Stock Option (right to buy) |
| 2018-08-13 | Smith Scott Clifford | Buy | 0 | |
| 2018-08-13 | Laffer Arthur B | Buy | 100 000 | Stock Option (right to buy) |
| INSIDER POWER |
|---|
| 0.00 |
| Last 13 transactions |
| Buy: 500 392 | Sell: 1 057 |
Forecast:
16:00 - $5.16
Live Trading Signals (every 1 min)
Forecast
1: 16:00 - $5.16
Forecast 2: 16:00 - $5.16
Forecast 3: 16:00 - $5.16
SCORE
10.00
Buy
10.00
Buy
Score Algorithm Version: 1.2C
Last version updated: Fri April 15th, 2022
Last version updated: Fri April 15th, 2022
| Indicator Signals | |
|---|---|
| RSI 21 | |
| SMA | |
| Trend | |
| Trend 2 | |
| Trend 3 | |
| MACD |
| Volume Signals | |
|---|---|
| Price | $5.19 (0.97% ) |
| Volume | 0.0418 mill |
| Avg. Vol. | 0.113 mill |
| % of Avg. Vol | 37.02 % |
| Signal 1: | |
| Signal 2: |
Today
Last 12 Months
RSI
Last 10 Buy & Sell Signals For EVO
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
| Date | Signal | @ | Closed | % |
|---|
EVO
Evotec SE operates as drug discovery and development partner for the pharmaceutical and biotechnology industry worldwide. The company is developing pharmaceutical products in various therapeutic areas, such as diabetes and complications of diabetes, fibrosis, infectious diseases, CNS diseases, oncology, pain and inflammation, immunology, rare diseases, respiratory diseases, and women's health. It has collaboration agreements with Bayer AG; Lilly; Chinook Therapeutics; Novo Nordisk A/S; Galapagos; Pfizer Inc.; CONBA Pharmaceutical Co., Ltd.; Bristol Myers Squibb Company; Zhejiang JingXin Pharmaceutical Co., Ltd; Kazia Therapeutics; Apeiron Biologics; and Takeda Pharmaceuticals. The company was formerly known as Evotec AG and changed its name to Evotec SE in April 2019. Evotec SE was incorporated in 1993 and is headquartered in Hamburg, Germany.
Last 10 Buy Signals
Latest Press Releases
2024-04-24 01:20:00 - Press Release
Evotec Presents Fiscal Year 2023 Results And Announces Priority Reset To Focus On Profitable Growth
Financial results for 2023 fully met updated guidance priority reset to profitable growth: size & footprint adjustments to drive expected annualised ebitda improvement greater than € 40 m evotec's reporting structure will change to business segments “shared r&d” and “just - evotec biologics” starting q1 2024 hamburg, germany / accesswire / april 24, 2024 / evotec se (frankfurt stock exchange:evt, mdax/tecdax, isin: de0005664809; nasdaq:evo) today reported financial results and corporate updates for the fiscal year ended 31 december 2023 and announced a priority reset to optimise its business to meet evolving market demand and focus on profitable growth in 2024 and beyond. continued growth despite multiple challenges group revenues up 4% to € 781...
2024-04-23 15:00:00 - Press Release
Evotec Se Appoints Dr Christian Wojczewski As Chief Executive Officer
Hamburg, germany / accesswire / april 23, 2024 / the supervisory board of evotec se (frankfurt stock exchange: evt, mdax/tecdax, isin: de0005664809; nasdaq:evo) has appointed dr christian wojczewski as the company's new chief executive officer ("ceo"), effective 01 july 2024. the election was unanimous and is the result of an extensive selection process that began in january.
2024-04-18 07:45:00 - Press Release
Evotec And Variant Bio Enter Strategic Partnership To Discover And Develop Fibrosis Treatments
Collaboration leverages variant bio's cutting-edge genomic discovery platform and evotec's integrated end-to-end r&d platform and disease area expertise to address unmet medical need in fibrotic indications commercial terms include research funding and milestones and/or royalty payments to evotec based on the overall success of the programme hamburg, germany and seattle, wa / accesswire / april 18, 2024 / evotec se (frankfurt stock exchange: evt, mdax/tecdax, isin: de0005664809; nasdaq:evo) and variant bio, inc. today announced a collaboration agreement to identify a best-in-class treatment for diseases caused by fibrosis. fibrosis is characterised by marked and pathogenic build-up of the tissue matrix, leading to tissue degeneration in organs, including the liver and lungs.
2024-04-18 07:27:00 - Press Release
Evotec And Variant Bio Enter Strategic Partnership To Discover And Develop Fibrosis Treatments
Collaboration leverages variant bio's cutting-edge genomic discovery platform and evotec's integrated end-to-end r&d platform and disease area expertise to address unmet medical need in fibrotic indications commercial terms include research funding and milestones and/or royalty payments to evotec based on the overall success of the program hamburg, germany and seattle , april 18, 2024 /prnewswire/ -- evotec se (frankfurt stock exchange: evt, mdax/tecdax, isin: de0005664809; nasdaq: evo) and variant bio, inc. today announced a collaboration agreement to identify a best-in-class treatment for diseases caused by fibrosis. the strategic partnership leverages variant bio's cutting-edge genomic discovery capabilities and vb-inference platform.
2024-04-17 09:15:00 - Press Release
Evotec Se To Announce Results For Fiscal Year 2023 On 24 April 2024
Hamburg, germany / accesswire / april 17, 2024 / evotec se (frankfurt stock exchange: evt, mdax/tecdax, isin: de0005664809; nasdaq:evo) will announce its financial results for 2023 on wednesday, 24 april 2024. the company is going to hold a conference call to discuss the results as well as provide an update on its performance.
Latest News
2024-04-24 09:41:02 - Seeking Alpha
Evotec: Still A Speculative Buy After A Significant Decline
2024-04-24 03:58:00 - Market Watch
Evotec shares lose a third of their value on cloudy outlook
Shares of German biotech Evotec lost a third of their value on Wednesday on an uncertain outlook as it named a new chief executive.
2024-04-17 09:15:00 - Accesswire
Evotec SE to Announce Results for Fiscal Year 2023 on 24 April 2024
HAMBURG, GERMANY / ACCESSWIRE / April 17, 2024 / Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809; NASDAQ:EVO) will announce its financial results for 2023 on Wednesday, 24 April 2024. The Company is going to hold a conference call to discuss the results as well as provide an update on its performance.
2024-03-20 09:44:13 - InvestorPlace
Finding the Next Big Winners: 7 Stocks You Can Snag for Under $10
If you're on the hunt for stocks under $10, look no further. The stock market has been off to a scorching start in 2024.
2024-03-06 13:04:56 - InvestorPlace
3 Stocks Set to Double: Your Fast Track to 2024 Gains
The stock market is soaring right now. It might seem too late to get in, given how far momentum stocks have already run up this year.
2024-03-04 10:38:24 - InvestorPlace
7 Stable Stocks to Buy for 100% Returns by 2025
The seven stable stocks discussed below each have the potential to double by 2025 based on analyst target prices. Each of the seven stocks is also relatively stable based on the fact that none have a beta higher than 1.4.
2024-01-22 15:43:08 - Seeking Alpha
Evotec SE (EVO) Business Update Conference Call (Transcript)
2024-01-22 02:00:00 - Accesswire
Evotec SE: Invitation to Conference Call
HAMBURG, GERMANY / ACCESSWIRE / January 22, 2024 / Evotec SE (Frankfurt Stock Exchange:EVT, MDAX/TecDAX, ISIN: DE0005664809; NASDAQ:EVO) is going to hold a conference call to provide a statement as well as a business update on Monday, 22 January 2024. During the call, the Chairwoman of Evotec's Supervisory Board, Prof.
2024-01-04 09:01:10 - InvestorPlace
Why Is Evotec (EVO) Stock Down 12% Today?
Evotec (NASDAQ: EVO ) stock is falling on Thursday after the drug discovery and development partner announced the resignation of CEO Dr. Werner Lanthaler. According to a press release from the company, Lanthaler departure is immediate and won't see him finish his term as leader of the company.
2023-11-12 20:42:37 - Seeking Alpha
Evotec: Attractive Spec 'Buy', But Merck KGaA Is Still Better
Evotec SE's appeal is based on its valuation and upside potential in the drug discovery and development sector. The company's financial performance is average, with negative margins and subpar business model specifics for 2022. Despite some issues, EVO remains a leading player in the drug/pharma market with strong partnerships and revenue growth.